Trexquant Investment LP Invests $416,000 in AMAG Pharmaceuticals, Inc. (AMAG) Stock

Trexquant Investment LP acquired a new stake in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) during the 3rd quarter, HoldingsChannel reports. The fund acquired 20,791 shares of the specialty pharmaceutical company’s stock, valued at approximately $416,000.

A number of other hedge funds have also added to or reduced their stakes in the stock. Legal & General Group Plc lifted its holdings in shares of AMAG Pharmaceuticals by 6.0% during the 2nd quarter. Legal & General Group Plc now owns 67,795 shares of the specialty pharmaceutical company’s stock valued at $1,341,000 after buying an additional 3,827 shares during the period. Alps Advisors Inc. lifted its holdings in shares of AMAG Pharmaceuticals by 9.0% during the 2nd quarter. Alps Advisors Inc. now owns 49,816 shares of the specialty pharmaceutical company’s stock valued at $971,000 after buying an additional 4,096 shares during the period. BNP Paribas Arbitrage SA lifted its holdings in shares of AMAG Pharmaceuticals by 8.5% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 88,180 shares of the specialty pharmaceutical company’s stock valued at $1,720,000 after buying an additional 6,883 shares during the period. Piedmont Investment Advisors LLC bought a new position in shares of AMAG Pharmaceuticals during the 2nd quarter valued at $156,000. Finally, HighPoint Advisor Group LLC bought a new position in shares of AMAG Pharmaceuticals during the 3rd quarter valued at $188,000.

Several equities analysts have recently weighed in on AMAG shares. Zacks Investment Research cut AMAG Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Friday, October 5th. Cantor Fitzgerald set a $18.00 price target on AMAG Pharmaceuticals and gave the company a “hold” rating in a report on Wednesday, September 26th. BidaskClub cut AMAG Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Tuesday, September 25th. Cowen set a $19.00 price target on AMAG Pharmaceuticals and gave the company a “hold” rating in a report on Thursday, November 1st. Finally, Deutsche Bank set a $23.00 price target on AMAG Pharmaceuticals and gave the company a “hold” rating in a report on Thursday, September 20th. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. AMAG Pharmaceuticals has an average rating of “Hold” and an average target price of $21.97.

Shares of AMAG Pharmaceuticals stock opened at $18.08 on Friday. AMAG Pharmaceuticals, Inc. has a one year low of $11.95 and a one year high of $26.10. The firm has a market capitalization of $616.12 million, a P/E ratio of -3.17 and a beta of 0.23. The company has a current ratio of 2.86, a quick ratio of 2.72 and a debt-to-equity ratio of 0.34.

AMAG Pharmaceuticals (NASDAQ:AMAG) last announced its earnings results on Thursday, November 1st. The specialty pharmaceutical company reported ($1.88) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.77) by ($1.11). AMAG Pharmaceuticals had a negative return on equity of 13.65% and a negative net margin of 6.98%. The company had revenue of $122.20 million during the quarter, compared to the consensus estimate of $118.23 million. During the same period in the prior year, the business posted ($4.31) earnings per share. AMAG Pharmaceuticals’s revenue for the quarter was down 1.7% compared to the same quarter last year. As a group, analysts forecast that AMAG Pharmaceuticals, Inc. will post -2.85 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This piece was first published by Markets Daily and is the sole property of of Markets Daily. If you are reading this piece on another site, it was copied illegally and reposted in violation of international copyright law. The correct version of this piece can be viewed at https://www.themarketsdaily.com/2018/12/07/trexquant-investment-lp-invests-416000-in-amag-pharmaceuticals-inc-amag-stock.html.

About AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc is a biopharmaceutical company, which focuses on the research, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. The firm focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia.

See Also: What does cost of debt say about a company’s financial health?

Want to see what other hedge funds are holding AMAG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG).

Institutional Ownership by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply